Resisting Resistance: Targeted Therapies in Lung Cancer

被引：172

作者：

Lin, Jessica J. ^{[1
]}

Shaw, Alice T. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Dept Thorac Oncol, Canc Ctr, 32 Fruit St, Boston, MA 02114 USA

来源：

TRENDS IN CANCER | 2016年 / 2卷 / 07期

关键词：

GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; EGFR T790M MUTATIONS; ACQUIRED-RESISTANCE; OPEN-LABEL; 1ST-LINE TREATMENT; CRIZOTINIB RESISTANCE; GEFITINIB RESISTANCE; MET AMPLIFICATION; RESIDUAL DISEASE;

D O I：

10.1016/j.trecan.2016.05.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Drug resistance inevitably limits the efficacy of all targeted therapies including tyrosine kinase inhibitors (TKIs). Understanding the biological underpinnings of TKI resistance is key to the successful development of future therapeutic strategies. Traditionally, mechanisms of TKI resistance have been viewed under a dichotomous lens. Tumor cells are TKI-sensitive or TKI-refractory, exhibit intrinsic or acquired resistance, and accumulate alterations within or outside the target to promote their survival. Such classifications facilitate our comprehension of an otherwise complex biology, but are likely an oversimplification. Recent studies underscore the multifaceted, genetically heterogeneous nature of TKI resistance, which evolves dynamically with changes in therapy. In this Review, we provide a broad framework for understanding the diverse mechanisms of resistance at play in oncogene-driven lung cancers.

引用

页码：350 / 364

页数：15

共 95 条

[21] The quest to overcome resistance to EGFR-targeted therapies in cancer [J].

Chong, Curtis R. ;

Jaenne, Pasi A. .

NATURE MEDICINE, 2013, 19 (11) :1389-1400

[22] Comprehensive molecular profiling of lung adenocarcinoma [J].

Collisson, Eric A. ;

Campbell, Joshua D. ;

Brooks, Angela N. ;

Berger, Alice H. ;

Lee, William ;

Chmielecki, Juliann ;

Beer, David G. ;

Cope, Leslie ;

Creighton, Chad J. ;

Danilova, Ludmila ;

Ding, Li ;

Getz, Gad ;

Hammerman, Peter S. ;

Hayes, D. Neil ;

Hernandez, Bryan ;

Herman, James G. ;

Heymach, John V. ;

Jurisica, Igor ;

Kucherlapati, Raju ;

Kwiatkowski, David ;

Ladanyi, Marc ;

Robertson, Gordon ;

Schultz, Nikolaus ;

Shen, Ronglai ;

Sinha, Rileen ;

Sougnez, Carrie ;

Tsao, Ming-Sound ;

Travis, William D. ;

Weinstein, John N. ;

Wigle, Dennis A. ;

Wilkerson, Matthew D. ;

Chu, Andy ;

Cherniack, Andrew D. ;

Hadjipanayis, Angela ;

Rosenberg, Mara ;

Weisenberger, Daniel J. ;

Laird, Peter W. ;

Radenbaugh, Amie ;

Ma, Singer ;

Stuart, Joshua M. ;

Byers, Lauren Averett ;

Baylin, Stephen B. ;

Govindan, Ramaswamy ;

Meyerson, Matthew ;

Rosenberg, Mara ;

Gabriel, Stacey B. ;

Cibulskis, Kristian ;

Sougnez, Carrie ;

Kim, Jaegil ;

Stewart, Chip .

NATURE, 2014, 511 (7511) :543-550

[23] The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial [J].

Costa, Carlota ;

Molina, Miguel Angel ;

Drozdowskyj, Ana ;

Gimenez-Capitan, Ana ;

Bertran-Alamillo, Jordi ;

Karachaliou, Niki ;

Gervais, Radj ;

Massuti, Bartomeu ;

Wei, Jia ;

Moran, Teresa ;

Majem, Margarita ;

Felip, Enriqueta ;

Carcereny, Enric ;

Garcia-Campelo, Rosario ;

Viteri, Santiago ;

Taron, Miquel ;

Ono, Mayumi ;

Giannikopoulos, Petros ;

Bivona, Trever ;

Rosell, Rafael .

CLINICAL CANCER RESEARCH, 2014, 20 (07) :2001-2010

[24] Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations [J].

Costa, Daniel B. ;

Schumer, Susan T. ;

Tenen, Daniel G. ;

Kobayashi, Susumu .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) :1182-1184

[25] Patient-derived models of acquired resistance can identify effective drug combinations for cancer [J].

Crystal, Adam S. ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Friboulet, Luc ;

Niederst, Matthew J. ;

Lockerman, Elizabeth L. ;

Frias, Rosa L. ;

Gainor, Justin F. ;

Amzallag, Arnaud ;

Greninger, Patricia ;

Lee, Dana ;

Kalsy, Anuj ;

Gomez-Caraballo, Maria ;

Elamine, Leila ;

Howe, Emily ;

Hur, Wooyoung ;

Lifshits, Eugene ;

Robinson, Hayley E. ;

Katayama, Ryohei ;

Faber, Anthony C. ;

Awad, Mark M. ;

Ramaswamy, Sridhar ;

Mino-Kenudson, Mari ;

Iafrate, A. John ;

Benes, Cyril H. ;

Engelman, Jeffrey A. .

SCIENCE, 2014, 346 (6216) :1480-1486

[26] Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer [J].

Davies, Kurtis D. ;

Mahale, Sakshi ;

Astling, David P. ;

Aisner, Dara L. ;

Le, Anh T. ;

Hinz, Trista K. ;

Vaishnavi, Aria ;

Bunn, Paul A., Jr. ;

Heasley, Lynn E. ;

Tan, Aik-Choon ;

Camidge, D. Ross ;

Varella-Garcia, Marileila ;

Doebele, Robert C. .

PLOS ONE, 2013, 8 (12)

[27] Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer [J].

de Bruin, Elza C. ;

Cowell, Catherine ;

Warne, Patricia H. ;

Jiang, Ming ;

Saunders, Rebecca E. ;

Melnick, Mary Ann ;

Gettinger, Scott ;

Walther, Zenta ;

Wurtz, Anna ;

Heynen, Guus J. ;

Heideman, Danielle A. M. ;

Gomez-Roman, Javier ;

Garcia-Castano, Almudena ;

Gong, Yixuan ;

Ladanyi, Marc ;

Varmus, Harold ;

Bernards, Rene ;

Smit, Egbert F. ;

Politi, Katerina ;

Downward, Julian .

CANCER DISCOVERY, 2014, 4 (05) :606-619

[28] Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer [J].

Doebele, Robert C. ;

Pilling, Amanda B. ;

Aisner, Dara L. ;

Kutateladze, Tatiana G. ;

Le, Anh T. ;

Weickhardt, Andrew J. ;

Kondo, Kimi L. ;

Linderman, Derek J. ;

Heasley, Lynn E. ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila ;

Camidge, D. Ross .

CLINICAL CANCER RESEARCH, 2012, 18 (05) :1472-1482

[29] A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer [J].

Drilon, Alexander ;

Somwar, Romel ;

Wagner, Jacob P. ;

Vellore, Nadeem A. ;

Eide, Christopher A. ;

Zabriskie, Matthew S. ;

Arcila, Maria E. ;

Hechtman, Jaclyn F. ;

Wang, Lu ;

Smith, Roger S. ;

Kris, Mark G. ;

Riely, Gregory J. ;

Druker, Brian J. ;

O'Hare, Thomas ;

Ladanyi, Marc ;

Davare, Monika A. .

CLINICAL CANCER RESEARCH, 2016, 22 (10) :2351-2358

[30] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Mitsudomi, Tetsuya ;

Song, Youngchul ;

Hyland, Courtney ;

Park, Joon Oh ;

Lindeman, Neal ;

Gale, Christopher-Michael ;

Zhao, Xiaojun ;

Christensen, James ;

Kosaka, Takayuki ;

Holmes, Alison J. ;

Rogers, Andrew M. ;

Cappuzzo, Federico ;

Mok, Tony ;

Lee, Charles ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

SCIENCE, 2007, 316 (5827) :1039-1043

← 1 2 3 4 5 6 7 8 9 10 →